Physician profile
Samia I Eid
NPI 1023071453
$3,210.33
in general payments reported to CMS, 2019-2025
30 companies · $15.35 in 2025
The $15.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $341 · 2021: $447 · 2022: $1,231 · 2023: $541 · 2025: $15.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.53 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $370.67 | 2019-2023 | Farxiga |
| Pfizer INC. | $304.55 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.18 | 2019-2025 | Xifaxan, Relistor |
| Lilly USA, LLC | $243.47 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $229.62 | 2019-2023 | Wegovy, Saxenda |
| Idorsia Pharmaceuticals US INC | $165.03 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $146.76 | 2021 | |
| Glaxosmithkline, LLC. | $101.16 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $98.11 | 2019-2022 | |
| Boston Scientific Corporation | $97.48 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.90 | 2020-2023 | Jardiance |
| Amgen INC. | $65.02 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $55.95 | 2022 | |
| Merck Sharp & Dohme LLC | $50.20 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $49.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.95 | 2020-2022 | |
| Astellas Pharma US INC | $38.02 | 2019-2020 | |
| Exact Sciences Corporation | $35.56 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $34.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.60 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.52 | 2019-2022 | |
| Edwards Lifesciences Corporation | $27.34 | 2022 | |
| Grifols USA, LLC | $19.86 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.01 | 2023 | Gvoke Hypopen |
| Vbi Vaccine (Delaware) INC. | $16.42 | 2022 | |
| Mannkind Corporation | $15.48 | 2019 | |
| Corium, LLC | $15.34 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.30 | 2020 | |
| Allergan, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samia Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.